Interní Med. 2001; 3(4): 156-160

Systolická hypertenze - fyziologický vzestup tlaku nebo cíl léčby

doc. MUDr. Jindřich ©pinar CSc, doc. MUDr. Jiří Vítovec CSc
II. interní klinika FN u sv. Anny LF MU, Brno

Keywords: systolic hypertension, old age, clinical studies.

Published: December 31, 2001  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©pinar J, Vítovec J. Systolická hypertenze - fyziologický vzestup tlaku nebo cíl léčby. Interní Med. 2001;3(4):156-160.

Autoři podávají přehled současných názorů na systolický krevní tlak, který, jak ukazují populační i intervenční studie, je významnějąím prognostickým faktorem neľ tlak diastolický. Jeho vzestup je pozorován předevąím se vzrůstajícím věkem a velmi těsně koreluje s mírou aterosklerózy. Jsou zmíněna domácí i zahraniční doporučení, která od loňského roku zahrnula výąku systolického krevního tlaku do základní klasifikace hypertenze, coľ je nezbytné pro provedení stratifikace rizika a zahájení léčby.

V druhé části jsou zmíněny nejprve klinické studie, které prokazují, ľe i léčba izolované systolické hypertenze vede ke sníľení úmrtnosti, ischemické choroby srdeční i cévních mozkových příhod. Zmíněna je velká klinická studie SHEP s diuretikem a SYST EUR s dihydropyridinem. Ná závěr jsou uvedeny výsledky klinické studie STOP II, která prokázala, ľe míra poklesu krevního tlaku je hlavním parametrem pro sníľení komplikací hypertenze.

Systolic Hypertension - the Physiologic Increase of Pressure or the Treatment Goal

Authors give a review of up-to-date opinions on systolic blood pressure, which is considered to be better prognostic factor than diastolic pressure according to population and intervention trials. Its increase is being observed due to aging and correlates closely with underlying progression of atherosclerosis. Authors mention inland and foreign recommendations, that have included level of systolic blood pressure into the basic classification of hypertension since last year. This has been proved to be necessary for risk stratification and therapy initiation.

In the second part of the article, at first there is a mention of clinical studies having proved that treatment of isolated systolic hypertension leads to reduction in over-all mortality, cardiac and cerebrovascular events. Then large clinical trials, SHEP trial with diuretics and SYST EUR trial with dihydropyridines, are described. Finally, results of the clinical trial STOP II are recounted. The data from this study confirm, that the value of lowering blood pressure is major determinant of reduction in complications due to hypertension.

Download citation

References

  1. Horký K., Widimský J. sen., Cífková R., Widimský J. jun.: Doporučení diagnostických a léčebných postupů u arteriální hypertenze. Guidelines České společnosti pro hypertenzi. Vnitřní lékařství 2000; 46: 5-13.
  2. Chalmers J., Mancia G., van Zwieten P.A.: 1999 World health OragnisationInternational Society of hypertension Guidelines for the Management of hypertension. Hypertension 1999; 17: 151-183. Go to original source...
  3. Kannel W.B., Gordon T., Schwarz M.J.: Systolic versus diastolic blood pressure and risk of coronary heart disease: Framingham Study. Am J Cardiol 1971; 27: 335-345. Go to original source... Go to PubMed...
  4. Kaplan, N.M.: Clinical Hypertension, Baltimore, Williams and Wilkins, Seventh Edition, 1998; 444 s.
  5. Messerli, F.H. : The ABCs of Antihypertensive Therapy. New York, Raven Press 1994; 280 s.
  6. Neaton J.D., Wentrworth D.: Serum cholesterol, blood pressure, cigarette smoking and death from coronary heart disease: overal findings and difference by age for 316 099 white men: Multiple Risc Factor Intervention Trial (MRFIT). Arch Intern med 1992; 152: 52-64. Go to original source...
  7. Rowland M., Roberts J.,: Blood pressure levels and hypertension in persons aged 6-74 years: United States 1976-1980. NCHS Advance Data, No 84, Health Statistics. US.
  8. Seux M.L., Forette F., Staessen J.A. za. řeąitele SYST-EUR: SYST-EUR - Systolic Hypertension-Europe. Randomized double blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Eur Heart J 1999; 1(Suppl M): M6-M12.
  9. SHEP řeąitelé : Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991 265: 3255-3264. Go to original source...
  10. STOP Hypertension 2 Investigators: Swedish Trial in Old Patients with Hypertension 2. Lancet 1999; 354: 1751-1756.
  11. ©pinar J., Vítovec J., Zicha J a kol.: Hypertenze, diagnostika a léčba, Grada 1999; 228 s.
  12. ©tejfa M.: Kardiologie. Druhé přepracované a doplněné vydání. Praha, Grada 1998; 500 s.
  13. The Sixth Report of the JNC on Prevention, Detection. Evalution of High Blood Pressure. Arch. Int. Med. 1997; 157: 2413-2452. Go to original source...
  14. Vítovec J., ©pinar J.: Faramakoterapie kardiovaskulárních onemocnění, Grada 2000: 249 s.
  15. Vítovec J., ©pinar J.: Hypertension and Combination Drug Therapy, Cor Vasa 2000; 42 (9): 461-467.
  16. Widimský J.: Léčba hypertenze - její pokrok v posledních 50 letech. Cor Vasa 1995; 37: 73-75.
  17. Widimský J.: Hypertenze. Diagnóza a léčba. Jinočany, Edice PL 1998; 227 s.
  18. Zanchetti A., Bond M.G., Hennig M. et al: Risk factors associated with alterations in carotid intima media thickness in hypertension: baselina data from ELSA. J of Hypertension 1998; 16: 949-961. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.